Home / Press Releases / Leidos Earns US Patent for Peptide-Based Treatment for Cancer, Infectious Diseases

Leidos Earns US Patent for Peptide-Based Treatment for Cancer, Infectious Diseases

TYSONS CORNER, VA, January 8, 2018 — The Leidos (NYSE: LDOS) life sciences business unit has been awarded a patent for peptide-based PD-1 checkpoint inhibitors via the U.S. Patent and Trademark Office‘s accelerated application review process for cancer immunotherapy-related discoveries, ExecutiveBiz reported Friday.

The company said Thursday the Leidos Health Life Sciences team worked on methods that use peptides as an alternative therapeutic platform to the monoclonal antibody molecule class of therapeutics for cancer and infectious diseases in an effort to increase safety while limiting cost.

About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com

Contact:
Jason Scott
(703) 226-7003
jason.scott@executivemosaic.com

Check Also

John Kavanaugh Notes Perspecta Portfolio, Contract Base at Baird-Hosted Conference

TYSONS CORNER, VA, December 2, 2019 — John Kavanaugh, senior vice president and chief financial officer of Perspecta (NYSE: PRSP), has said the company maintains a diversified contract base, balanced portfolio and strong backlog during his keynote address at Baird’s 2019 Government & Defense Conference, ExecutiveBiz reported Nov. 20.

Boeing Starliner Test Dummy Named ‘Rosie the Astronaut’; Leanne Caret Quoted

TYSONS CORNER, VA, November 27, 2019 — The test dummy for Boeing's (NYSE: BA) initial orbital flight test of the Starliner space taxi will be called "Rosie the Astronaut" in honor of a World War II icon, ExecutiveBiz reported Tuesday.